A typical bedside-to-bench investigation of leukemogenic driver MEF2D fusion reveals new targeted therapy in B-cell acute lymphoblastic leukemia.
A typical bedside-to-bench investigation of leukemogenic driver MEF2D fusion reveals new targeted therapy in B-cell acute lymphoblastic leukemia.
复制标题
一项典型的致白血病驱动因子MEF2D融合的床旁到实验室研究揭示了B细胞急性淋巴细胞白血病的新靶向治疗。
DOI：
10.1097/bs9.0000000000000126
复制
发表时间：
2022-07
期刊：
影响因子：
1
通讯作者：
Meng, Guoyu
中科院分区：
文献类型：
--
作者：
Zhang, Hao;Meng, Guoyu
B细胞急性淋巴细胞白血病(B-ALL)是一种起源于B系淋巴前体细胞的恶性肿瘤。B-ALL在儿童急性白血病中的发病率约为80%，在成人中约为20%。近年来，在风险分层指导下的规范治疗下，儿童的长期无病存活率约为80%，而成人的长期无病存活率不到40%。然而，新发现的B-ALL的具体发病机制和靶向治疗策略尚未得到大力研究。在这篇综述中，我们重点介绍了DUX4和MEF2D亚型B-ALL在机制研究和新的治疗选择方面的最新突破。
B-cell acute lymphoblastic leukemia (B-ALL) is a malignant tumor originating from B-lineage lymphoid precursor cells. The incidence of B-ALL is about 80% in childhood acute leukemia and 20% in adults. In recent years, with standardized treatment guided by risk stratification, the long-term disease-free survival rate of children is about 80%, while that of adults is less than 40%. However, the specific pathogenesis of the newly identified B-ALL and the targeted therapy strategies have not been vigorously investigated. In this review, we highlight the recent breakthroughs in mechanistic studies and novel therapeutic options in DUX4- and MEF2D-subtype B-ALLs.
DUX4HD2-DNAERG 结构揭示了对 DUX4 响应元件的新见解
影响因子：
11.4
作者：
Dong X;Zhang H;Cheng N;Li K;Meng G
通讯作者：
Meng G